Low-Dose Naltrexone (LDN): A Functional Medicine Approach to Autoimmunity, Lyme Disease, Long COVID, and Chronic Illness

Yoon Hang Kim, MD, MPH

Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician

Introduction

Low-dose naltrexone (LDN) has emerged as one of the most compelling yet underutilized tools in functional and integrative medicine. Over the past two decades, clinicians worldwide have increasingly incorporated LDN into treatment protocols for autoimmune disease, chronic infections, and complex inflammatory syndromes, including Lyme disease, long COVID, and mast cell activation syndrome (MCAS).

Unlike conventional immunosuppressive therapies that blunt the immune system broadly, LDN works by modulating immune function, helping the body recalibrate its own regulatory mechanisms. This distinction makes LDN uniquely suited for root-cause, systems-based medicine. At standard doses of 50 mg, naltrexone functions as a full opioid receptor antagonist and is FDA-approved for the treatment of opioid and alcohol use disorders. At low doses, typically ranging from 0.5 to 4.5 mg, the pharmacological profile shifts dramatically, producing immunomodulatory, anti-inflammatory, and analgesic effects through distinct mechanisms [1, 2].

Mechanisms of Action

Understanding why LDN works requires examining three interconnected biological pathways.

Endorphin Modulation and the OGF-OGFr Axis

LDN transiently blocks opioid receptors for approximately four to six hours when taken at bedtime. This brief blockade triggers a compensatory upregulation of both endogenous opioid peptides, particularly opioid growth factor (OGF, also known as met-enkephalin), and their receptors (OGFr). The resulting rebound increase in endorphin activity modulates immune surveillance, regulates cell proliferation, and supports tissue homeostasis [3, 4]. This mechanism was first explored clinically in 1985 by Dr. Bernard Bihari, who used LDN in the treatment of HIV/AIDS patients and observed improvements in immune function [5].

Toll-Like Receptor 4 (TLR4) Antagonism and Microglial Regulation

A second, mechanistically distinct pathway involves the antagonism of Toll-like receptor 4 (TLR4) on microglial cells within the central nervous system. TLR4 activation on microglia triggers the release of pro-inflammatory cytokines, including interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), driving neuroinflammation and central sensitization. LDN inhibits this TLR4-mediated activation, thereby reducing neuroinflammatory cascades that contribute to brain fog, chronic fatigue, widespread pain, and cognitive dysfunction [1, 6, 7]. Research by Younger and colleagues at Stanford demonstrated that this anti-inflammatory effect is likely independent of the opioid receptor mechanism, occurring through a non-stereoselective interaction with TLR4 [6].

Immune System Rebalancing

Rather than suppressing immunity, as conventional disease-modifying agents do, LDN helps restore balance between pro-inflammatory and anti-inflammatory immune responses. Evidence suggests that LDN may modulate the Th1/Th2 balance, dampen inflammatory signaling, and support regulatory T cell (Treg) function. Additionally, LDN has been shown to reduce pro-inflammatory cytokines, including IL-6 and TNF-α, in patients with fibromyalgia after eight weeks of treatment [8]. This immune-normalizing effect makes LDN particularly relevant in conditions characterized by immune dysregulation rather than immune deficiency.

Why LDN Is Not One-Size-Fits-All: The Critical Importance of Individualized Dosing

One of the most persistent and clinically consequential misconceptions about LDN is that a single standard dose works for everyone. In practice, inter-individual variability in response is substantial.

The Spectrum of Dosing

Some patients tolerate and respond well to the commonly cited dose range of 1.5 to 4.5 mg taken at bedtime. Others require ultra-low doses in the microgram range, a practice that remains underutilized in clinical settings. Still others experience an initial symptom flare or worsening upon starting LDN, often reflecting underlying endorphin deficiency or heightened neuroinflammatory tone rather than true drug intolerance [1]. This variability reflects a core tenet of functional medicine: biology is individualized, and protocol-based dosing frequently fails to account for the complexity of the individual patient.

Clinical Pitfall: Premature Discontinuation

Failure to individualize dosing is the single most common reason patients abandon LDN therapy prematurely. Side effects such as vivid dreams, transient headache, or initial symptom amplification typically resolve with dose adjustment or slower titration. Clinicians experienced with LDN recognize that patience and careful dose titration are essential for optimizing outcomes.

LDN in Autoimmune Disease

LDN has demonstrated clinical benefit across multiple autoimmune conditions, including Hashimoto’s thyroiditis, Sjögren’s syndrome, rheumatoid arthritis, multiple sclerosis, Crohn’s disease, and inflammatory bowel disease.

Evidence in Crohn’s Disease

The strongest controlled evidence for LDN in autoimmune disease comes from the work of Smith and colleagues at Penn State. In an open-label pilot trial, patients with active Crohn’s disease (CDAI scores 220–450) treated with 4.5 mg naltrexone daily demonstrated significant clinical improvement, with 89% of patients achieving a response and 67% achieving remission [9]. A subsequent randomized, placebo-controlled trial confirmed that LDN promoted mucosal healing in active Crohn’s disease [10]. A Cochrane systematic review acknowledged these findings while noting the need for larger, multi-center replication studies [11].

Evidence in Multiple Sclerosis

Two randomized, placebo-controlled trials have evaluated LDN in multiple sclerosis. Cree and colleagues at UCSF conducted a double-masked, crossover study in 80 MS patients, finding a significant improvement in mental health quality of life during the LDN treatment period [12]. Sharafaddinzadeh et al. conducted a parallel-group trial in 96 MS patients, reporting improvements in several quality-of-life domains [13]. An observational study spanning up to ten years demonstrated that patients receiving LDN maintained stable neurological status and laboratory values over prolonged treatment periods [14].

Clinical Effects Across Autoimmune Conditions

Across autoimmune conditions, clinicians and observational studies have reported reductions in inflammatory markers and, in some patients with Hashimoto’s thyroiditis, decreases in thyroid peroxidase (TPO) and thyroglobulin (TG) antibody levels over three to six months of therapy. Symptomatic improvements in fatigue, pain, and quality of life have been consistently observed, with some patients able to reduce concurrent immunosuppressive medications [15, 16]. It is important to note that early intervention tends to yield better outcomes. Advanced, end-stage autoimmune disease may not reverse, but patients frequently experience meaningful symptomatic improvement.

LDN, Diet, and Metabolic Health

LDN works best when embedded within a comprehensive treatment strategy that includes dietary intervention. However, no single universal diet exists for all patients with chronic illness. Patients respond differently to ketogenic, plant-based, Mediterranean, autoimmune elimination, and mixed dietary approaches. The best diet is the one the patient can sustain over time while supporting metabolic and immune health.

When combined with appropriate dietary changes, LDN may contribute to improved insulin sensitivity, lower fasting blood glucose, and, in select cases, support type 2 diabetes remission as part of a broader metabolic rehabilitation strategy. These metabolic effects are likely mediated through the reduction of systemic inflammation and normalization of immune signaling rather than direct glucose-lowering mechanisms.

The Overlap: Lyme Disease, Long COVID, and Mast Cell Activation Syndrome

Modern chronic illness frequently involves overlapping syndromes that share common pathophysiological mechanisms: post-infectious immune dysregulation, chronic inflammation, neuroinflammation, and autoimmune activation.

Long COVID and LDN

The emergence of long COVID has dramatically expanded interest in LDN as a therapeutic intervention. O’Kelly and colleagues published a landmark interventional pre-post study in 2022, treating 38 patients with Post-COVID-19 Syndrome using LDN at 1–3 mg/day for two months. Patients experienced improvements in six of seven parameters assessed, including energy, pain, concentration, and sleep disturbance, with a safety rate of 94.7% [17]. Bonilla et al. at Stanford reported that LDN was associated with reduced symptom burden and improved functional performance in long COVID patients [18]. A recent systematic review and meta-analysis pooling four observational studies (n=155) found moderate effects for reducing fatigue (Hedges’ g = -0.74) with LDN treatment [19]. LDN has also been shown to restore TRPM3 ion channel function in natural killer cells from long COVID patients, providing a mechanistic link between LDN therapy and improved immune cell function [20].

Shared Immune Dysfunction Model

Lyme disease, long COVID, and MCAS share a common model of immune dysfunction: persistent immune activation following an infectious trigger, with subsequent dysregulation of mast cells, microglia, and T-cell function. LDN addresses several nodes in this dysregulation simultaneously through its dual action on opioid receptors and TLR4. However, multimodal therapy is required in these complex patients, and LDN should be understood as a cornerstone within a broader therapeutic strategy, not a standalone treatment.

Lyme Disease: A Complex Chronic Illness

Lyme disease, caused by Borrelia burgdorferi and related species, represents one of the most challenging chronic infections in clinical medicine. Its complexity arises from the organism’s slow growth rate, its ability to evade immune detection through antigenic variation and intracellular persistence, the poor sensitivity of standard two-tier serological testing, and the wide variability of clinical presentations across patients.

Effective management of chronic or persistent Lyme disease typically requires a multimodal approach that may include targeted antimicrobial therapy (such as doxycycline, dapsone, or rifampin), herbal antimicrobial protocols, immune modulation with LDN, anti-inflammatory strategies, and attention to co-infections and concurrent immune dysregulation. Lyme disease frequently requires long-term management rather than short-term curative treatment, a clinical reality that demands patience, individualization, and the integration of multiple therapeutic modalities.

The Functional Medicine Approach: Beyond Protocol-Based Care

An effective strategy for chronic illness combines multiple therapeutic tools: pharmaceuticals when appropriate, nutritional therapy, herbal medicine, immune modulation with LDN, and lifestyle optimization. The goal is not adherence to a fixed protocol but the delivery of precision, individualized medicine tailored to each patient’s unique biology, history, and clinical trajectory.

This approach requires a practice model that prioritizes low patient volumes and high-attention care. High-complexity patients with overlapping conditions such as autoimmunity, chronic infection, MCAS, and neuroinflammation cannot be adequately served in high-volume clinical settings constrained by seven- to fifteen-minute appointments. Functional medicine prioritizes effectiveness over efficiency, and this philosophical commitment is reflected in models such as direct care and concierge medicine.

Limitations of Conventional Care and the Evidence Base for LDN

Many patients with chronic illness struggle within conventional medical systems that were designed primarily for acute care. Chronic, multi-system conditions are often dismissed, under-investigated, or managed with symptom-suppressive monotherapy rather than root-cause-oriented strategies.

It is equally important to acknowledge the limitations of the current evidence base for LDN. While the clinical rationale is strong, the published literature consists primarily of small pilot trials, open-label studies, and observational data. Large, multi-center, randomized controlled trials are limited, due in part to the fact that naltrexone is an inexpensive generic medication with limited commercial incentive for pharmaceutical-funded research. Several well-designed trials are currently underway, including a multicentre randomized controlled trial for LDN in Crohn’s disease in the Netherlands [21] and clinical trials evaluating LDN in post-COVID fatigue syndrome [22]. The field awaits these results with significant interest.

Conclusion

LDN represents a paradigm shift in the treatment of chronic illness. It modulates rather than suppresses immune function. It requires careful individualization of dosing and integration within a comprehensive, systems-based treatment plan. It addresses shared pathophysiological mechanisms across autoimmune disease, chronic infection, post-infectious syndromes, and neuroinflammatory conditions.

For patients with autoimmune disease, Lyme disease, long COVID, MCAS, or chronic inflammatory conditions, LDN may be one of the most important and underutilized tools available in contemporary medicine. As the evidence base continues to grow, LDN’s role in integrative and functional medicine practice is likely to expand significantly.

References

1. Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451–459. doi:10.1007/s10067-014-2517-2. PMID: 24526250.

2. Patten DK, Schultz BG, Berlau DJ. The safety and efficacy of low-dose naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, Crohn’s disease, and other chronic pain disorders. Pharmacotherapy. 2018;38(3):382–389. doi:10.1002/phar.2086. PMID: 29377216.

3. Zagon IS, McLaughlin PJ. Opioid growth factor and the treatment of human pancreatic cancer: a review. World J Gastroenterol. 2014;20(9):2218–2223. doi:10.3748/wjg.v20.i9.2218. PMID: 24605021.

4. Li Z, You Y, Griffin N, Feng J, Shan F. Low-dose naltrexone (LDN): a promising treatment in immune-related diseases and cancer therapy. Int Immunopharmacol. 2018;61:178–184. doi:10.1016/j.intimp.2018.05.020. PMID: 29885638.

5. Bihari B. Bernard Bihari, MD: low-dose naltrexone for normalizing immune system function. Altern Ther Health Med. 2013;19(2):56–65. PMID: 23594453.

6. Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med. 2009;10(4):663–672. doi:10.1111/j.1526-4637.2009.00613.x. PMID: 19453963.

7. Hutchinson MR, Zhang Y, Brown K, et al. Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4). Eur J Neurosci. 2008;28(1):20–29. doi:10.1111/j.1460-9568.2008.06321.x. PMID: 18662331.

8. Parkitny L, Younger J. Reduced pro-inflammatory cytokines after eight weeks of low-dose naltrexone for fibromyalgia. Biomedicines. 2017;5(2):16. doi:10.3390/biomedicines5020016. PMID: 28536359.

9. Smith JP, Stock H, Bingaman S, Mauger D, Rogosnitzky M, Zagon IS. Low-dose naltrexone therapy improves active Crohn’s disease. Am J Gastroenterol. 2007;102(4):820–828. doi:10.1111/j.1572-0241.2007.01045.x. PMID: 17222320.

10. Smith JP, Bingaman SI, Ruggiero F, et al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn’s disease: a randomized placebo-controlled trial. Dig Dis Sci. 2011;56(7):2088–2097. doi:10.1007/s10620-011-1653-7. PMID: 21380937.

11. Segal D, Macdonald JK, Chande N. Low dose naltrexone for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2018;4:CD010410. doi:10.1002/14651858.CD010410.pub2. PMID: 29607497.

12. Cree BAC, Kornyeyeva E, Goodin DS. Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Ann Neurol. 2010;68(2):145–150. doi:10.1002/ana.22006. PMID: 20695007.

13. Sharafaddinzadeh N, Moghtaderi A, Kashipazha D, Majdinasab N, Shalbafan B. The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial. Mult Scler. 2010;16(8):964–969. doi:10.1177/1352458510366857. PMID: 20534644.

14. Ludwig MD, Turel AP, Zagon IS, McLaughlin PJ. Long-term treatment with low dose naltrexone maintains stable health in patients with multiple sclerosis. Mult Scler J Exp Transl Clin. 2016;2:2055217316672242. doi:10.1177/2055217316672242. PMID: 28607740.

15. Raknes G, Simonsen P, Småbrekke L. The effect of low-dose naltrexone on medication in inflammatory bowel disease: a quasi experimental before-and-after prescription database study. J Crohns Colitis. 2018;12(6):677–686. doi:10.1093/ecco-jcc/jjy008. PMID: 29385430.

16. Gironi M, Martinelli-Boneschi F, Sacerdote P, et al. A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis. Mult Scler. 2008;14(8):1076–1083. doi:10.1177/1352458508095828. PMID: 18728058.

17. O’Kelly B, Vidal L, McHugh T, Woo J, Avramovic G, Lambert JS. Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study. Brain Behav Immun Health. 2022;24:100485. doi:10.1016/j.bbih.2022.100485. PMID: 35814187.

18. Bonilla H, Tian L, Marconi VC, et al. Low-dose naltrexone use for the management of post-acute sequelae of COVID-19. Int Immunopharmacol. 2023;124:110966. doi:10.1016/j.intimp.2023.110966.

19. Effenberger M, et al. Does low-dose oral naltrexone alleviate symptoms of long COVID? A systematic review and meta-analysis. COVID. 2025;5(12):198. doi:10.3390/covid5120198.

20. Cabanas H, et al. Low-dose naltrexone restored TRPM3 ion channel function in natural killer cells from long COVID patients. Front Mol Biosci. 2025;12:1582967. doi:10.3389/fmolb.2025.1582967.

21. Paulides E, Lie MRKL, van der Woude CJ. Low-dose naltrexone for the induction of remission in patients with mild to moderate Crohn’s disease: protocol for the randomised, double-blinded, placebo-controlled, multicentre LDN Crohn study. BMJ Open. 2022;12(4):e058358. doi:10.1136/bmjopen-2021-058358. PMID: 35396307.

22. ClinicalTrials.gov. Low-dose naltrexone for post-COVID fatigue syndrome. Identifier: NCT05430152. National Library of Medicine. 2022.

About the Author

Yoon Hang Kim, MD, MPH is a board-certified physician in Preventive Medicine and Integrative & Functional Medicine and the founder of www.directintegrativecare.com a membership-based telemedicine practice. He is a recognized LDN expert and author, an Osher Fellow through the University of Arizona Andrew Weil Center for Integrative Medicine, an IFM Scholarship Recipient, and underwent UCLA Medical Acupuncture training. Dr. Kim brings over 20 years of experience in integrative and functional medicine, including leadership roles in integrative oncology at academic medical centers. He leads the LDN Support Group, an educational community of over 9,000 members.

Learn more: www.directintegrativecare.com